Drug eluting balloons for the treatment of coronary artery disease: What can we expect?

doi:10.4330/wjc.v2.i9.257

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 9

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3053)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series.

Item

Count

PDF

476

HTML

2400

Figures (1-4)

177

Sum=3053

Sep 26, 2010 (publication date) through Sep 19, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Cardiol. Sep 26, 2010; 2(9): 257-261
Published online Sep 26, 2010. doi: 10.4330/wjc.v2.i9.257

Full Size Figure Download Figure

Figure 3 Treatment of in-stent-restenosis using a drug eluting balloon (paclitaxel-releasing balloon) vs a drug-eluting stent (paclitaxel-eluting stent). Left columns: Rate of binary in-segment restenosis (%) after 6 mo; Right columns: Major adverse cardiac events (MACE, including target lesion revascularization, myocardial infarction, stent thrombosis, or death) (%) after 12 mo[9]. DEB: Drug-eluting balloon; DES: Drug-eluting stents.

Citation: Joost A, Kurowski V, Radke PW. Drug eluting balloons for the treatment of coronary artery disease: What can we expect? World J Cardiol 2010; 2(9): 257-261
URL: https://www.wjgnet.com/1949-8462/full/v2/i9/257.htm
DOI: https://dx.doi.org/10.4330/wjc.v2.i9.257